# Study of N-Acetylcysteine in Acute Liver Failure (ALF)

> **NCT00896025** · PHASE4 · TERMINATED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 255 (actual)

## Conditions studied

- Acute Liver Failure
- Fulminant Hepatic Failure

## Interventions

- **DRUG:** N-acetylcysteine

## Key facts

- **NCT ID:** NCT00896025
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2015-10-15
- **Final completion:** 2016-03
- **Target enrollment:** 255 (ACTUAL)
- **Why stopped:** This observational study was stopped after 140 patients were enrolled, no more funds available to continue.
- **Last updated:** 2020-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896025, "Study of N-Acetylcysteine in Acute Liver Failure (ALF)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00896025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*